The Technical Analyst
Anchiano Therapeutics Ltd [CMMB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Anchiano Therapeutics Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.91% $0.673
America/New_York / 19 apr 2024 @ 13:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.55 mill |
| EPS: | -2.06 |
| P/E: | -0.330 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 14.20 mill |
| Avg Daily Volume: | 0.228 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.330 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -0.330 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.764 (13.58%) $0.0913 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.616 - 0.730 ( +/- 8.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-14 | Darvish Nissim | Buy | 20 572 | Option to Purchase American Depositary Shares |
| 2021-04-19 | Darvish Nissim | Buy | 11 884 | Option to Purchase American Depositary Shares |
| 2016-10-28 | Darvish Nissim | Buy | 10 123 | Option to Purchase American Depositary Shares |
| 2023-03-16 | Darvish Nissim | Buy | 6 857 | Option to Purchase American Depositary Shares |
| 2022-03-07 | Darvish Nissim | Buy | 6 820 | Option to Purchase American Depositary Shares |
| INSIDER POWER |
|---|
| -58.06 |
| Last 88 transactions |
| Buy: 2 375 207 | Sell: 4 584 307 |
Forecast:
15:29 - $0.683
Live Trading Signals (every 1 min)
Forecast
1: 13:59 - $0.672
Forecast 2: 14:49 - $0.702
Forecast 3: 15:29 - $0.683
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.673 (-3.91% ) |
| Volume | 0.0106 mill |
| Avg. Vol. | 0.228 mill |
| % of Avg. Vol | 4.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CMMB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Latest Press Releases
2024-04-18 07:00:00 - Press Release
Chemomab Reports New Peer-reviewed Publication Reinforcing The Clinical Association Of Its Ccl24 Target With Disease Severity And Mortality In Patients With Systemic Sclerosis
Peer-reviewed patient study validates chemomab's ccl24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
2024-04-02 07:00:00 - Press Release
Chemomab To Host Virtual Key Opinion Leader Webinar On Primary Sclerosing Cholangitis On April 10, 2024
Chemomab's kol primary sclerosing cholangitis virtual event on april 10 at 10:00 am et will include physician & patient psc experts & a live q&a session.
2024-03-25 07:06:00 - Press Release
Chemomab Awarded New European Patent For Cm-101, Its First-in Class Monoclonal Antibody In Phase 2 Clinical Development For Primary Sclerosing Cholangitis
Chemomab has gained a new eu patent for cm-101 covering its use in liver diseases including psc, adding to the robust patent estate in major territories.
2024-03-07 07:00:00 - Press Release
Chemomab Therapeutics Announces Year End And Fourth Quarter 2023 Financial Results And Provides A Corporate Update
─accelerated phase 2 cm-101 psc trial timeline with topline 15-week data now planned for midyear 2024 and topline open label data expected in late 2024/early 2025 ─ ─cash runway extended through end of first quarter 2025 as a result of early completion of phase 2 psc trial and effective financial management─ ─2023 achievements position chemomab for a potentially transformational 2024─ tel aviv, israel , march 7, 2024 /prnewswire/ -- chemomab therapeutics, ltd. (nasdaq: cmmb), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the full year and fourth quarter ended december 31, 2023, and provided a corporate update.
2024-03-05 07:00:00 - Press Release
Chemomab Therapeutics To Participate In Leerink Global Biopharma Conference
Tel aviv, israel , march 5, 2024 /prnewswire/ -- chemomab therapeutics ltd. (nasdaq: cmmb) (chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that ceo dr. adi mor will deliver a corporate presentation and participate in investor meetings at the leerink partners global biopharma conference, march 11-13, 2024 in miami, florida.
Latest News
2023-11-16 13:32:05 - Zacks Investment Research
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
2023-05-14 11:20:23 - Seeking Alpha
Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.
2023-03-06 07:00:00 - PRNewsWire
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.
2023-02-21 11:43:23 - InvestorPlace
Chemomab (CMMB) Stock Gains 30% on FDA Clearance
There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.
2023-02-21 08:25:00 - Market Watch
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.
2022-11-11 12:00:27 - Seeking Alpha
Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.
2022-10-28 07:00:00 - PRNewsWire
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.
2022-08-12 14:40:21 - Seeking Alpha
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.
2022-08-01 07:00:00 - PRNewsWire
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.
2022-05-18 07:00:00 - PRNewsWire
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.